Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David James McConkey, Primo Lara, Maha H. A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Fred Hutch Cancer Center, Children's Hospital of Los Angeles, Illinois CancerCare, University of Iowa Hospitals and Clinics, University of Iowa Health Care, University of Iowa Holden Comprehensive Cancer Center, Johns Hopkins University, Johns Hopkins Hospital, University of California System, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Comprehensive Cancer Centers of Nevada, Christus Santa Rosa Health System, University of Utah, Huntsman Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3030240402